Floatz logo

Sonovue

Cerebrovascular Stroke

University of California, Los AngelesPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Cerebrovascular Stroke cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Nerinetide
NoNO Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

Sonovue is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
carotid stenosisDormant
B
Indicative ·
62 / 100
View asset →
atherosclerosisDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →